Adaptimmune Therapeutics plc
ADAPNASDAQHealthcare
$0.05
$-0.00(-3.00%)
Market Cap$75157679
P/E Ratio—
52W High$0.86
52W Low$0.0202
Adaptimmune Therapeutics plc (ADAP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ADAP · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.18B | $0.06B | $0.03B | $0.01B | $0.00B |
| Cost of Revenue | $0.00B | $0.01B | $0.13B | $0.11B | $0.09B |
| Gross Profit | $0.18B | $0.05B | ($0.10B) | ($0.10B) | ($0.09B) |
| Gross Margin %(computed) | 99.96% | 83.65% | -370.48% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.15B | $0.13B | $0.13B | $0.11B | $0.09B |
| G&A Expenses | $0.08B | $0.07B | $0.06B | $0.06B | $0.05B |
| Total Operating Expenses | $0.25B | $0.19B | $0.19B | $0.17B | $0.14B |
| Operating Income | ($0.07B) | ($0.14B) | ($0.16B) | ($0.16B) | ($0.13B) |
| Operating Margin %(computed) | -38.62% | -228.99% | -603.97% | — | — |
| Interest Income | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.07B) | ($0.11B) | ($0.16B) | ($0.16B) | ($0.13B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.07B) | ($0.11B) | ($0.17B) | ($0.16B) | ($0.13B) |
| Net Margin %(computed) | -39.78% | -188.90% | -609.46% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.28 | $-0.57 | $-1.02 | $-1.02 | $-0.90 |
| Wtd Avg Shares | 0.25B | 0.20B | 0.16B | 0.16B | 0.14B |
| EBITDA | ($0.05B) | ($0.13B) | ($0.16B) | ($0.16B) | ($0.13B) |
| EBITDA Margin %(computed) | -29.58% | -212.67% | -573.13% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Adaptimmune Therapeutics plc data
About Adaptimmune Therapeutics plc (ADAP) Income Statement
Adaptimmune Therapeutics plc (ADAP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, ADAP reported revenue of $0.18B, gross profit of $0.18B (gross margin 99.96%), and net income of ($0.07B) — a net profit margin of -39.78%.
Frequently asked questions
ADAP · 4 questionsAdaptimmune Therapeutics plc (ADAP) reported revenue of $0.18B for 2024, up 195.3% year-over-year.
ADAP revenueADAP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08